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Ampullary cancer is a rare gastrointestinal malignancy that can be curable with 
surgical resection of localized disease. The benefit of adjuvant therapy, however, 
remains unknown in these patients partly because of difficulty in stratifying which 
patients are at high risk for recurrence. To better identify those patients who may 
benefit from adjuvant therapy, I conducted a retrospective analysis the pathology 
reports from 176 patients with surgically resected ampullary cancer who had not 
received any neoadjuvant therapy, the systemic therapy given, and the patient 
outcomes.  A tissue microarray (TMA) of 95 surgically resected ampullary 
specimens was also constructed to examine whether there is a correlation between 
classical immunohistochemical profiles for intestinal and pancreaticobiliary tumors 
and their histologic classification. In this study, I confirmed the prognostic value of 
advanced T-stage, nodal metastases, and lymphovascular invasion. Patients whose 
tumors had “high risk” features had a significantly worse overall survival (p=.002). 
Furthermore, my research highlighted the importance of histology and its impact on 
survival, with pancreaticobiliary-like features being a negative prognostic factor 
(p=0.001). Importantly, patients whose tumors have pancreaticobiliary histology 
appear to benefit from adjuvant therapy, further implicating histology as an 
important pathologic marker (p=0.053).  In addition, the TMA confirmed a 
vi 
correlation between classical immunohistochemical profiles for intestinal and 
pancreaticobiliary tumors and histologic classification. My research findings suggest 
that histology subtypes, T-stage, nodal metastases, and lymphovascular invasion 
should all be taken into consideration when determining which patients with 
ampullary cancer may benefit from further adjuvant therapy.    
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Chapter 1 
INTRODUCTION 
 
Ampullary cancer.  The ampulla of Vater is located at the junction of the main 
pancreatic duct and the distal common bile duct within the head of the pancreas. 
The ampulla opens into the duodenum and thus cancers arising in the ampulla of 
Vater are composed of three different types of epithelium: pancreas, biliary, and 
small intestine [1]. Ampullary cancers make up 0.5% of all gastrointestinal 
malignancies with 5,625 cases reported in the Surveillance, Epidemiology, and End 
Results (SEER) database between 1973 and 2005. There has been a rise in the 
incidence of ampullary cancer over the past twenty-five years and the disease 
afflicts men more than women. The five-year overall survival rate for localized 
disease is 45% compared to 4% for patients with metastatic disease [2]. The 
cancer-specific five-year survival for resected ampullary cancer is 47.3 months [1]. 
Ampullary cancer has a better prognosis than distal common bile duct tumors and 
pancreatic cancer. This could be due to the fact that patients present at an earlier 
stage with obstructive jaundice, but data also points to ampullary cancer having a 
different biology than pancreaticobiliary cancers.  The curative surgery for localized 
ampullary cancer is the Whipple resection, or pancreaticoduodenectomy. However, 
even with surgery, patients whose tumors have certain pathologic features are at a 
high risk of recurrence of disease. 
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Risk factors for the development of ampullary carcinoma.  The precise risk 
factors for ampullary cancer are not clearly identified; however there is an 
association between this disease and Familial Adenomatous Polyposis (FAP). FAP 
is a genetic syndrome, caused by an inherited mutation in the APC gene, in which 
patients develop hundreds to thousands of polyps throughout the bowel. Colon 
cancer is most commonly associated with this mutation, but the risk of developing 
ampullary cancer with FAP is increased by 100-200% with a prevalence of 3-12% 
[3]. Accordingly, routine endoscopic evaluation of the duodenum and ampulla of 
Vater is recommended in patients with FAP. The colon cancer that develops in 
those with FAP involves the classic progression of adenoma to carcinoma, and thus 
it is thought that this same progression may be of pivotal importance in ampullary 
carcinogenesis as well [4].  Adenomas have been identified in as many as 90% of 
surgical specimens of ampullary cancer, and it has been demonstrated that over 
half of adenoma specimens may include areas of invasive carcinoma [5,6]. 
 
Intestinal versus pancreaticobiliary histology.  Ampullary cancer has more 
recently been identified as being a heterogeneous disease with the histologic 
patterns of each tumor varying between a spectrum of intestinal and 
pancreaticobiliary differentiation [7,8,9,10]. This spectrum was first described by 
Kimura and colleagues who analyzed the histologic features of 53 ampullary cancer 
specimens and found that pancreaticobiliary-type tumors had more frequent nodal 
metastases and a worse overall outcome [9]. Since then, further 
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immunohistochemical characterization has been suggested based on a variety of 
markers, including: CK7, CK20, CK17, CDX2, and MUC1 [7,8,10].  
 
Prognostic factors and the definition of “high risk” subpopulations. A number 
of prognostic factors have been described in both localized and advanced ampullary 
cancer. The revised American Joint Committee on Cancer (AJCC) staging of 
ampullary cancer recognizes the importance of tumor invasion into the surrounding 
pancreas (T3 and T4 lesions) and lymph node metastases (N1) as two relevant 
prognostic factors in ampullary carcinoma [11]. For example, a single institution 
study of 127 patients with ampullary cancer demonstrated a better median survival 
in patients with Tis-T2 tumors compared to those with invasion into the pancreas 
(60 months versus 26 months, p=0.025) [12]. Furthermore, a review of 1301 cases 
of resected ampullary cancer in the SEER database showed that the 5-year cancer-
specific survivals for patients without and with lymph node metastases were 59.4% 
and 28.4%, respectively, highlighting the importance of lymph node status [13]. 
Other prognostic factors reported in the literature include poorly differentiated 
tumors, positive margins at the time of resection, and lymphovascular invasion 
[12,13,14,15,16]. More recently, the histology classifications of pancreaticobiliary 
versus intestinal have been suggested as prognostic, with ampullary cancers falling 
into the pancreaticobiliary subtype demonstrating a worse overall survival [14,17].  
 
In patients with resected ampullary cancer, risk of recurrence correlates with the 
presence of these previously mentioned adverse factors. These prognostic 
4 
variables help define a “high risk” group in whom further adjuvant chemotherapy 
and/or chemoradiation may provide an absolute benefit. A number of different 
prognostic factors have been incorporated in this definition, but most retrospective 
studies include T3/T4 tumors, positive lymph nodes, poorly differentiated histology, 
lymphovascular invasion, and positive resection margins as indicators of patients at 
“high risk” for recurrence [18,19,20].  
 
Approach to adjuvant therapy in localized disease.  Adjuvant therapy in 
resected ampullary carcinoma is typically reserved for patients at “high risk” for 
relapse, but the actual role of chemotherapy versus chemoradiation remains largely 
undefined. Most studies addressing this question are single-institution, retrospective 
analyses, thereby limiting the ability to draw definitive conclusions. Radiation 
therapy has played a role in adjuvant therapy because of the historically high rate of 
locoregional recurrence [21,22]. Adjuvant radiation has historically been reserved 
for patients whose tumors have poor prognostic features including T stage, nodal 
metastases, and positive margins of resection [18,20,23,24]. Sytemic 5-fluorouracil 
or capecitabine are typically given with radiation. However, as the R0 resection rate 
after pancreaticoduodenectomy has improved, the rate of distant relapse has 
remained a continued problem, suggesting the need for more effective systemic 
chemotherapy either alone or in conjunction with chemoradiation [16,25]. 
While 5-fluorouracil-based chemoradiation has been widely accepted for adjuvant 
therapy, the precise chemotherapies that provide maximum benefit remain unclear. 
Historically, ampullary cancers have been grouped under biliary tract cancers, 
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making gemcitabine the standard backbone of chemotherapy in advanced disease. 
However, a phase II study at MD Anderson Cancer Center (MDACC) of 
capecitabine and oxaliplatin in advanced small bowel and ampullary cancers 
demonstrated an improved response rate and overall survival when compared to 
historical controls [26]. Interestingly, the response rate in ampullary cancers was 
lower than that in small bowel cancers (33% versus 61%, respectively). Our group 
at MDACC hypothesized that this may have been due to differences in tumor 
histology among the ampullary cancer patients, with those tumors not responding to 
a 5-fluorouracil-based regimen possibly having a pancreaticobiliary subtype. We 
analyzed the role of chemotherapy in the adjuvant setting in this retrospective 
review, but did not see a survival improvement when chemotherapy was added to 
chemoradiation. The true benefit of chemotherapy may be magnified, however, 
when patients are stratified by histology. 
 
Ampullary cancer is treated with surgical resection followed by adjuvant therapy in 
patients who are at “high risk” for recurrence. The precise pathologic markers that 
define “high risk” have been debated in the literature. Furthermore, ampullary 
cancers with pancreaticobiliary histology have a worse prognosis, but this factor has 
not been routinely included in the typical “high risk” definition. In addition, it remains 
unclear what benefit adjuvant therapy offers patients who have these “high risk” 
features, specifically because the components of what should constitute adjuvant 
therapy is controversial. 
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Summary. Ampullary cancer is a rare malignancy for which the role of adjuvant 
therapy remains unclear. As more is understood about the classification of these 
tumors into intestinal and pancreaticobiliary subtypes, it is possible that the benefit 
of adjuvant therapy may depend not only on the presence of specific prognostic 
features, but also on histology.  
 
For my Master’s research project, I performed a retrospective analysis of 176 
patients with resected ampullary cancer who were treated at MDACC between 1990 
and 2009 to determine which tumor factors impacted upon overall survival and 
possibly predict for the benefit of adjuvant therapy. My research confirmed that 
T3/T4, nodal metastases, lymphovascular invasion, and pancreaticobiliary histology 
were associated with a worse overall survival. Furthermore, in a multivariate 
analysis of the “high risk” patients, I found a survival benefit seen with adjuvant 
therapy. We also demonstrated a possible benefit to adjuvant therapy in the 
pancreaticobiliary subtype of ampullary cancer, but this needs to be confirmed in a 
larger patient population. 
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Chapter 2 
METHODS 
 
Retrospective chart review: 
This retrospective chart review was approved by the Institutional Review Board at 
MDACC. The MDACC tumor registry was queried for patients seen at our institution 
from 1990 to 2009 with a diagnosis of ampullary cancer. From this group, we 
collected further clinical information only on patients who specifically had a 
resectable ampullary cancer and who underwent a pancreaticoduodenectomy at 
MDACC or at an outside institution. This retrospective review included 176 cases of 
resected ampullary cancer after excluding patients who received neoadjuvant 
therapy.  
 
Basic demographic information was collected on all 176 patients including age and 
gender. Additionally, the date of surgery and any chemotherapy or chemoradiation 
given in the adjuvant setting were recorded. Surgical pathology features were 
noted, including: T stage by AJCC staging, lymph node metastases present and the 
lymph node ratio (number of positive lymph nodes divided by the total number of 
lymph nodes sampled), presence of adenoma, histologic differentiation (well, 
moderately, poorly), positive or negative margin of resection, and lymphovascular 
invasion. Based upon previous literature, the patients were stratified as “high risk” of 
recurrence if they had T3/T4 tumors, nodal metastases, poorly differentiated 
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histology, lymphovascular invasion, or positive surgical margins 
[11,12,13,14,15,16]. 
Preparation of tissue microarray of resected ampullary cancers:  
We collected available tissue specimens on 95 of the 176 patients who underwent 
pancreaticoduodenectomy at MDACC between 1995 and 2009.  None of these 
patients had received neoadjuvant chemotherapy and/or radiation. These 95 tissue 
specimens were examined by our pathologist collaborating on this study (Dr. 
Huamin Wang) and categorized as either pancreaticobiliary, intestinal, or mixed 
histology.  
 
To construct the ampullary tissue microarray used in this study, formalin-fixed, 
paraffin-embedded archival tissue blocks and their matching hematoxylin and eosin-
stained (H & E) slides were retrieved, reviewed and screened for representative 
tumor regions by our pathologist (Dr. Wang).  For each patient, two cores of tumor 
were sampled from the tissue blocks from representative areas using a 1.0-mm 
punch. Under the direction of Dr. Wang, the tissue microarray was constructed with 
a tissue microarrayer (Beecher Instruments, Sun Prairie, WI) as described 
previously [27]. 
 
Histology and immunohistochemistry analysis of tissue microarray: 
In Dr. Wang’s lab, the tissue microarray (TMA) prepared for each tumor was stained 
for two cytokeratin markers, CK7 and CK20, which typically represent a 
pancreaticobiliary and intestinal histology, respectively. The TMA also tested for 
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staining of caudal type homeobox 2 (CDX2) which has previously been described 
as a pathologic prognostic marker in ampullary cancer and has been hypothesized 
to be more indicative of an intestinal-type tumor in this disease [8].  
 
The methodology for the TMA has been detailed in a prior manuscript [28]. To 
summarize, immunohistochemical stains were performed on 5 μm unstained 
sections from the tissue microarray blocks using three antibodies listed in Table 1. 
To retrieve the antigenicity, the tissue sections were treated at 100 °C in a steamer 
containing 10 mmol citrate buffer (pH 6.0) for 60 min. The sections were then 
immersed in methanol containing 0.3% hydrogen peroxidase for 20 min to block the 
endogenous peroxidase activity and were incubated in 2.5% blocking serum to 
reduce nonspecific binding. Sections were incubated for 90 min at 37 °C with 
primary antibodies at the dilutions specified in Table 1. Standard avidin–biotin 
immunohistochemical analysis of the sections was performed according to the 
manufacturer's recommendations (Vector Laboratories, Burlingame, CA, USA). 
Diaminobenzidine tetrahydrochloride was used as a chromogen, and haematoxylin 
was used for counterstaining. 
 
Table 1.  Antibodies used for tissue microarray analysis 
Antibody  Clone  Titre  Company  
Anti-CDX2 CDX-88 1 : 50 Biogenex, San Ramon, CA, USA 
Anti-CK7 OVT-TL 12/30 1 : 100 Dako, Carpinteria, CA, USA 
Anti-CK20 KS20.8 1 : 4000 Dako, Carpinteria, CA, USA 
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Statistical Analysis:   
Summary statistics were used to describe the clinical and demographic 
characteristics of the study population. We used Pearson chi-square test (or 
Fisher’s exact test) to assess differences between patients with different histologies 
and immunohistochemical markers. 
 
For overall survival, the time to death or censoring was calculated in months since 
date of surgery for each patient.  Overall survival was censored at the date of last 
follow-up if death was not observed. For recurrence-free survival, the time to 
recurrence was calculated in months since date of surgery for each patient. 
Recurrence-free survival was censored at the date of last follow-up if recurrence or 
death was not observed.  Univariate Cox proportional hazards regression was used 
to model the association between each potential prognostic factor and overall 
survival and recurrence-free survival [29]. A p-value of <0.05 was determined to be 
statistically significant. The Kaplan-Meier product limit method was used to estimate 
the median overall survival and relapse-free survival [30].     
 
The multivariate proportional hazard model for overall survival showed a full model 
with all the variables that were significant in the univariate analysis and a reduced 
model after selecting variables through backwards selection methods.  The 
histology variables of intestinal/mixed and pancreaticobiliary were each further 
analyzed using univariate Cox proportional hazards regression to model an 
association between histology and any adjuvant therapy. 
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Statistical analysis was performed using STATA/SE version 12.0 statistical software 
(Stata Corp. LP, College Station, TX). 
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Chapter 3 
RESULTS 
 
Clinical and pathologic characteristics of patients 
Table 2 summarizes the clinical and pathologic characteristics of the patients. Of 
the 176 patients reviewed, the mean age of diagnosis was 60.6 years. With regard 
to “high risk” tumor features, 52.8% of patients had nodal metastases, 43.8% of 
patients had T3/T4 tumors, 35.3% had tumors with poorly differentiated histology, 
39.2% had tumors with lymphovascular invasion, and 4% had tumors with positive 
margins of resection. While 69.3% of patients were deemed “high risk” after 
resection (n=122), only 50% of all patients received adjuvant chemotherapy, 
radiation therapy or chemotherapy plus radiation (n=88). The remainder entered 
surveillance after surgery. Among all patients in this series, radiation therapy was 
given to 40.9% of patients and only 30.1% of patients received systemic 
chemotherapy either alone or in conjunction with radiation.  
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Table 2.  Clinical/pathologic characteristics in 176 patients with ampullary cancer 
Age at diagnosis   
     N 176  
     Mean (SD)     60.6 (12.3)  
 N % 
Pathologic Stage    
     1 1      0.7 
     2 58     39.2 
     3 89     60.1 
Pathologic T stage   
     T0 - T2 99     56.3 
     T3 - T4 77     43.8 
Grade   
     Unknown 2      1.2 
     Well 17      9.8 
     Moderate 93     53.8 
     Poor 61     35.3 
Lymphovascular Invasion (LVI)   
     No 107     60.8 
     Yes 69     39.2 
Lymph Node (LN) Involvement   
     No 83     47.2 
     Yes 93     52.8 
LN Ratio Groups   
     0 83     47.4 
     0-0.2 50     28.6 
     >0.2 42     24.0 
Surgical Margins   
     Negative 169     96.0 
     Positive 7      4.0 
High Risk    
     No 54     30.7 
     
   Yes  
 
Adjuvant 
122     69.3 
     No 88     50.0 
     Yes 88     50.0 
Systemic Chemotherapy   
     None 123     69.9 
     5-fluorouracil 38     21.6 
     Gemcitabine 12      6.8 
     5-fluorouracil+Gemcitabine 3      1.7 
 N % 
14 
Adjuvant Treatment   
     None 88     50.0 
     Chemotherapy Only 16      9.1 
     Chemotherapy + Radiation 37     21.0 
     Radiation only  35     19.9 
Recurrence   
     No 90     51.4 
     Yes 85     48.6 
Vital Status   
     Alive 86     48.9 
     Dead 90     51.1 
Recurrence   
     Early ≤12months 64     36.4 
     Late >12months 112     63.6 
First Recurrence   
     None  88     50.0 
     Local Recurrence 15      8.5 
     Metastasis 71     40.3 
     Unknown 2      1.1 
 
Survival analysis  
Median follow-up for all 176 patients was 38.1 months. The median overall survival 
of the entire group was 62.3 months (Figure 1). As summarized in Table 2, 48.9% of 
patients were still alive at the time of analysis, and importantly, of the 48.6% of 
patients who had recurrent disease, close to two-thirds of them were late 
recurrences (> 12 months after surgery). Recurrent disease was primarily 
metastatic disease rather than locoregional recurrence. 
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Figure 1. Overall survival of 176 patients with resected ampullary cancer
 
 
“High risk” features correlate with overall survival and recurrence 
122 of the patients in this analysis were categorized as “high risk” based on the 
previously described pathologic characteristics. Tables 3 and 4 summarize the 
impact of these “high risk” features on overall survival and relapse-free survival 
(RFS), respectively, by univariate analysis.  
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Table 3. Univariate proportional hazards regression model - Overall survival 
 N 
No. of 
deaths 
Median time 
(months) 
Hazard 
Ratio 
 (HR) 
95% CI 
 for HR 
HR 
p-
value 
Log-
rank 
p-value 
T Stage        
     T0-T2 99 49 84.80     
     T3/T4 77 41 38.64 2.17 (1.40, 3.36) 0.001 <0.001 
Grade        
    Well 17 13 66.60     
    Moderate 93 44 62.75 0.75 (0.40, 1.41) 0.379 0.394 
    Poor 61 32 38.93 1.01 (0.53, 1.95) 0.971  
LVI        
     No 107 52 84.80     
     Yes 69 38 42.09 2.15 (1.38, 3.34) 0.001 0.001 
LN Positive        
     No 83 41 84.80     
     Yes 93 49 45.93 1.54 (1.01, 2.34) 0.046 0.044 
LN Ratio         
     0 83 41 84.80     
     0-0.2 50 19 75.10 0.91 (0.53, 1.58) 0.739 <0.001 
     >0.2 42 29 24.41 2.82 (1.73, 4.61) <0.001  
Surgical 
Margins 
       
     Negative 169 85 62.75     
     Positive 7 5 21.85 2.13 (0.86, 5.28) 0.102 0.094 
High Risk        
     No 54 25 97.15     
     Yes 122 65 44.42 2.11 (1.31, 3.41) 0.002 0.002 
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Table 4. Univariate proportional hazards regression model – RFS 
 
 
 
N 
No. of 
events 
Median time 
(months) 
Hazard 
Ratio 
 (HR) 
95% CI 
 for HR 
HR 
p-
value 
Log-
rank 
p-
value 
T Stage        
     T0/T2 99 59 40.71     
     T3/T4 77 51 18.20 1.70 (1.16,  2.49) 0.007 0.006 
Grade        
     Well 17 15 16.82     
     Moderate 93 52 41.79 0.58 (0.33,  1.03) 0.064 0.034 
     Poor 61 41 20.01 0.93 (0.52,  1.69) 0.823  
LVI        
     No 107 63 37.68     
     Yes 69 47 20.01 1.66 (1.13,  2.45) 0.010 0.009 
LN Positive        
     No 83 49 36.53     
     Yes 93 61 23.98 1.34 (0.92,  1.95) 0.129 0.127 
LN Ratio         
     0 83 49 36.53     
     0-0.2 50 22 45.08 0.72 (0.44,  1.20) 0.205 <0.001 
     >0.2 42 38 11.07 2.72 (1.77,  4.19) <0.001  
Surgical Margins        
     Negative 169 105 29.27     
     Positive 7 5 13.31 1.95 (0.79,  4.81) 0.148 0.140 
High Risk         
     No 54 29 54.51     
     Yes 122 81 20.67 1.81 (1.18,  2.77) 0.007 0.006 
 
Patients who were defined as “high risk” had a significantly decreased overall 
survival (p=0.002, Figure 2) and relapse-free survival (p=0.006) compared to those 
patients who did not have advanced T-stage, nodal metastases, poorly 
differentiated histology, lymphovascular invasion, or positive surgical margins. 
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Figure 2. Patients with “high risk” features have a worse overall survival 
 
The most notable predictors for survival and recurrence included T stage, lymph 
node ratio, and lymphovascular invasion. Patients with T3 or T4 tumors had a 
median overall survival of 38.6 months versus 84.8 months for patients with T0-T2 
lesions (HR 2.17, p<0.001).  Lymph node ratio has been previously described by 
our group at MDACC as being a better predictor of survival in small bowel 
adenocarcinoma than the total number of positive lymph nodes [31]. Similarly, in our 
cohort of patients, lymph node ratio was strongly correlated with survival and 
recurrence. In patients with a lymph node ratio of >0.2, median overall survival was 
only 24.4 months compared to 84.8 months in patients with no positive lymph nodes 
(HR 2.82, p<0.001). Additionally, lymphovascular invasion increased risk of death 
and relapse, with a HR of 2.15 for overall survival (p=0.001). 
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 Interestingly, poorly differentiated histology and positive surgical margins did not 
significantly impact survival or recurrence, although the lack of impact of a positive 
surgical margin may be reflective of the small number of patients with this (n=7).  It 
is important to note, however, that these results are different than what has been 
previously reported in the literature. 
 
Intestinal histology predicts for improved overall survival 
Representative slides of intestinal/mixed and pancreaticobiliary histologies are 
shown in Figure 3. Univariate analysis demonstrated that patients with an intestinal 
or mixed histology (n=60) had a better overall survival compared to patients with a 
pancreaticobiliary-like tumor (n=34) (Figure 4; 108.3 months versus 55.4 months, 
HR 2.23, p=0.001).  Our findings validate previous reports, but in a larger set of 
patients. 
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Figure 4. Intestinal/mixed histology has a better overall survival than 
pancreaticobiliary 
 
Relapse-free survival was also improved in the intestinal histology group, but this 
difference did not meet statistical significance (data not shown).  
 
Multivariate analysis confirmed the prognostic value of histology as well. Patients 
with a pancreaticobiliary histology had a hazard ratio of 3.37 for death relative to 
intestinal-like tumors (p=0.012). This stratification was equally striking in terms of 
risk of recurrence with a pancreaticobiliary histology compared to an intestinal one 
(HR 8.87, p=0.003). 
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Multivariate analysis of “high risk” patients demonstrates benefit to adjuvant therapy 
To better assess the benefit of adjuvant therapy in our “high risk” population of 
patients, we performed a multivariate analysis involving all of the prognostic 
variables that were significant by univariate analysis.  In the 122 “high risk” patients, 
there is a survival benefit to adjuvant therapy, but this did not reach statistical 
significance (HR 0.39, p=0.071). A similar trend was seen for relapse-free survival 
in this same cohort (HR 0.37, p=0.06). When looking at the entire population of 176 
patients, there was also a trend towards a benefit in overall survival with adjuvant 
therapy, but interestingly, this was in patients who received adjuvant chemotherapy 
or chemoradiation therapy alone (n=51; HR 0.34, p=0.059). Patients receiving 
chemotherapy followed by chemoradiation in the adjuvant setting did not 
demonstrate an improvement in overall survival (n=37; HR 0.52, p=0.351). 
 
Tissue microarray analysis  
The ampullary tissue microarray included tumor tissue from 95 of the 176 resected 
ampullary patients. We correlated patients’ histology subtypes with the following 
immunohistochemical markers: CK7, CK20, CDX2. Our findings are summarized in 
Table 5. While the percentage of surgical specimens that was CK7 positive were 
relatively equal, only 5.7% of the tumors with a pancreaticobiliary histology were 
CK20 positive, compared to 51.7% in the intestinal/mixed tumors (p<0.001). Tumors 
that were CK7 positive and CK20 negative, the classic immunohistochemical profile 
for upper gastrointestinal tract cancers, were seen more prominently in specimens 
with a pancreaticobiliary histology (p=0.011). In addition, CDX2 positivity, typically 
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seen in intestinal cancers, was seen significantly more frequently in the 
intestinal/mixed histology tumors (p=0.028). Importantly, though these 
immunohistochemical markers correlated with histology, they were not 
independently associated with survival or recurrence by univariate analysis. 
 
Table 5. Tissue microarray analysis  
 
All Patients 
TMA Histology 
p-value 
 Intestinal/Mixed Pancreas 
 N % N % N %  
TMA CK7       0.782a 
     Negative 26 27.4 17 28.3 9 25.7  
     Positive 69 72.6 43 71.7 26 74.3  
TMA CK20       <0.001b 
     Negative 62 65.3 29 48.3 33 94.3  
     Positive 33 34.7 31 51.7 2 5.7  
TMA CK7+ CK20-       0.011a 
     Negative 46 48.4 35 58.3 11 31.4  
     Positive 49 51.6 25 41.7 24 68.6  
TMA CDX2       0.028a 
     Negative 54 56.8 29 48.3 25 71.4  
     Positive 41 43.2 31 51.7 10 28.6  
a Pearson chi-square 
b Fisher’s exact test 
 
Pancreaticobiliary histology may benefit from adjuvant therapy  
To assess if there were a correlation between adjuvant therapy and histology, we 
looked at the tumors of 95 patients with pancreaticobiliary and intestinal histologies 
and stratified them by treatment. These univariate analyses included a small 
number of patients, but there was a suggestion that adjuvant therapy may benefit 
patients with pancreaticobiliary histology. Figure 4 demonstrates the overall survival 
curves for patients with pancreaticobiliary histology who received any form of 
adjuvant therapy versus those who entered surveillance after surgery (n=20 
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patients who received adjuvant therapy and 14 who did not; p=0.053). Patients with 
an intestinal/mixed tumor did not see this same overall survival benefit (n=23 
patients who received adjuvant therapy and 37 who did not; p=0.535). These 
findings have not been previously reported in the literature, and are clinically 
relevant as they suggest that all patients with pancreaticobiliary-like tumors should 
receive further therapy after surgery.  
 
Figure 5. Pancreaticobiliary histology may benefit from adjuvant therapy  
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Chapter 4 
DISCUSSION 
Ampullary cancer is a rare malignancy of the gastrointestinal tract, and thus, there is 
little data on the role of adjuvant therapy (chemotherapy, radiation therapy or both). 
Retrospective analyses have identified a number of different prognostic factors that 
help classify patients as “high risk” for recurrence. These include: T3/T4 tumors, 
lymph node involvement, poorly differentiated histology, lymphovascular invasion, 
and positive surgical margins of resection. In this analysis, I reviewed MDACC’s 
experience with resected ampullary cancer in 176 patients seen at our institution 
from 1990-2009. We investigated the validity of the prognostic pathologic features 
that have been reported previously in the literature and explored other potential 
pathologic markers that may be of added value in determining which patients may 
benefit from adjuvant therapy after surgical resection of their ampullary cancer. 
 
My analysis represents one of the largest reports on resected ampullary cancer in 
the literature. I identified the “high risk” features of advanced T-stage (T3/T4 
tumors), nodal metastases, and lymphovascular invasion as being significantly 
associated with reduced overall survival and relapse-free survival. Additionally, I 
demonstrated that those patients who were classified as “high-risk” of recurrence 
based on pathologic features not only have a worse overall survival but they also 
benefit from adjuvant therapy after surgical resection. As has been described in a 
number of other series, lymph node involvement was one of the strongest predictors 
for recurrence [12,32].  
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My research did not, however, validate poorly differentiated histology and positive 
surgical margins as important prognostic markers. This was a striking observation 
given the previous findings in the literature of poorly differentiated histology as a 
poor prognostic factor [14]. This finding may be due to grade being a confounding 
variable; those patients with poorly differentiated tumors could be more likely to 
have nodal metastases, for instance. It is further important to note that only 7 
patients had positive surgical margins, making it difficult to accurately measure 
margin status as it relates to survival. In the combined retrospective study done by 
Johns Hopkins and Mayo Clinic, a similar lack of association was seen due to small 
numbers of positive surgical margins [16]. However, the steady improvement in the 
R0 resection rate for pancreaticoduodenectomies may diminish the impact of 
margin status and locoregional recurrences in ampullary cancer patients and 
increase the importance of effective chemotherapy. 
 
Interestingly, in our series, the majority of patients relapsed with distant metastases, 
suggesting a need for the use of adjuvant systemic therapy or better chemotherapy. 
This pattern of systemic rather than locoregional recurrence has been reported in 
other studies although the frequent use of chemoradiation in “high risk” patients 
may have decreased local recurrence rates [16,33,34]. Interestingly, chemotherapy 
followed by chemoradiation in our study did not show a survival benefit when 
compared to chemoradiation alone. This may stem from the fact that the patients 
who were selected to receive chemotherapy followed by chemoradiation had worse 
prognostic features after surgery, and thus received more aggressive adjuvant 
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therapy. The exact role of chemotherapy as an adjunct to chemoradiation remains 
unclear, but the high rate of distant failure in our study implies that ampullary cancer 
is a systemic disease for which better chemotherapy options are needed. 
 
Using a TMA, my research, in collaboration with Dr. Wang’s lab, further identified a 
correlation between histology subtype and overall survival with pancreaticobiliary-
like tumors having a worse overall survival than intestinal/mixed tumors. This 
concurs with the findings reported in other studies [14,35]. In contrast, some other 
reports have implied that these differences in survival are not as striking [36,37]. 
Importantly, these studies did demonstrate that patients with pancreaticobiliary-like 
tumors have a worse prognosis, but these differences did not reach statistical 
significance.  
 
My results further showed that patients with the pancreaticobiliary subtype benefit 
from adjuvant therapy, though the small sample size precludes our ability to make 
definitive recommendations. This finding has not been previously reported by other 
groups, and is clinically relevant in our approach to resected ampullary patients. It 
merits further investigation in a larger set of patients. Tissue microarray analysis 
also showed that the histology classifications correspond to the typical 
immunohistochemical profiles seen for pancreaticobiliary and intestinal tumors. It is 
important to note, however, that the immunohistochemical markers did not correlate 
with survival, implying that histology is a more useful prognostic indicator for this 
disease. Taken together, our results demonstrate the role of histologic classification 
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in identifying those patients who are at a higher risk for recurrence and who may 
derive the greatest benefit from adjuvant therapy after surgical resection. 
 
My retrospective review of MDACC’s experience with surgically resected ampullary 
cancer confirms the prognostic value of specific pathologic features in this disease. 
As has been previously reported in the literature, surgical pathology and histology 
should be evaluated to determine which patients may benefit from adjuvant therapy. 
Our group did not validate the previously reported prognostic value of poorly 
differentiated histology or surgical margins. We did confirm advanced T-stage, 
nodal metastases, and lymphovascular invasion as relevant prognostic markers. 
We also demonstrated the importance of histology subtypes over 
immunohistochemical profiling when identifying “high risk” patients and highlighted 
the benefit of adjuvant therapy in patients with pancreaticobiliary-like tumors. 
 
Our study does not clarify the question of whether chemotherapy and 
chemoradiation should both be given to decrease local recurrence and distant 
failure rates. This limitation is primarily due to the small sample size and the 
retrospective nature of this analysis. Further studies are needed to ascertain what 
components of adjuvant therapy improve overall survival in patients who are “high 
risk” for recurrence and to validate the role of histology in defining a “high risk” 
population.  
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Chapter 5 
STRENGTHS AND WEAKNESSES 
This retrospective analysis has clinical relevance for ampullary cancer because it is 
a disease for which prospective data is very limited. My study included a relatively 
large sample size in comparison to previous reports in the literature. The population 
I examined was homogeneous in that the ampullary cancers had been resected and 
the patients had received no prior neoadjuvant therapy.  However, as with all 
retrospective analyses, this study has some limitations. 
 
MDACC is a referral center for rare malignancies such as ampullary cancer. There 
could have been a bias in the patient population that was analyzed in that close to 
70% of the patients were “high risk”, and this may not be reflective of the general 
population of resected ampullary cancer patients. Additionally, in my analysis of the 
benefit of adjuvant therapy in the “high risk” cohort, we included all pathologic 
features that were described in the literature as poor prognostic factors. However, in 
our final analysis, poorly differentiated histology and positive margins were not 
negative prognostic factors, and thus our assessment of the benefit of adjuvant 
therapy may have been skewed. Furthermore, given that all patients who receive 
adjuvant therapy are “high risk”, there is an inherent bias in prognosis that may 
have minimized the survival benefit of adjuvant therapy. In addition, this issue may 
have been more pronounced in patients who received chemotherapy followed by 
chemoradiation, as these patients may have been deemed especially “high risk” 
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based on the presence of multiple poor prognostic factors, thereby influencing the 
benefit of adding chemotherapy to chemoradiation.  
 
While the multivariate analysis attempted to mitigate this inherent bias, it is difficult 
to include all the factors that play into a physician’s decision tree when assessing 
the need for adjuvant therapy. For instance, data was lacking for performance 
status after surgery which can influence the decision to give adjuvant therapy and 
the type of treatment offered. Any delays in administering adjuvant therapy cannot 
be accounted for in this analysis as well.  
 
My results indicate that histologic subtypes correlate with overall survival, with 
pancreaticobiliary-like tumors having a worse prognosis than intestinal or mixed 
histology. This pathologic classification is subject to inter-reader variation, making it 
difficult to standardize among pathologists.  Lymphovascular invasion and tumor 
grade can also suffer from a similar bias [38,39]. This variability may have 
influenced which patients were labeled as “high risk” in this study. In future studies, 
if a “high risk” population is identified based on these pathologic criteria, it will be 
essential to standardize these assessments to ensure that the appropriate patients 
are captured. 
 
Finally, our finding that pancreaticobiliary histology may benefit from adjuvant 
therapy is based on an exploratory analysis of a small number of patients. As a 
result, this correlation is hypothesis- generating and requires a more robust 
31 
evaluation with a larger sample size. Our findings do suggest, however, that 
histology may be a more useful prognostic pathologic marker than 
immunohistochemistry. Furthermore, elaborating on what constitutes adjuvant 
therapy will be essential to truly understanding the magnitude of benefit in this 
subpopulation of ampullary cancer patients. 
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Chapter 6 
FUTURE DIRECTIONS 
This retrospective analysis highlights the importance of pathological markers of 
prognosis in ampullary cancer. Future studies in our group at MDACC will be 
directed at confirming the relevance of these markers with regard to adjuvant 
therapy and survival and understanding the differences in biology between 
pancreaticobiliary-like tumors and intestinal ones. Our future research will attempt to 
identify those patients who would benefit most from adjuvant therapy and what 
types of therapies should make up adjuvant treatment. 
 
My study results indicate that pancreaticobiliary subtypes of ampullary cancer 
benefit from adjuvant therapy. Our group’s next step in this project will be to 
collaborate with other institutions to obtain a larger dataset of resected ampullary 
patients. By doing so, we hope to validate histology as a new “high risk” factor. 
Additionally, we will study whether we can stratify patients by histology subtype and 
chemotherapy received to assess if gemcitabine-based therapy is more beneficial in 
pancreaticobiliary-like ampullary tumors while 5-fluorouracil-baased chemotherapy 
should be reserved for intestinal or mixed histology tumors. Furthermore, we hope 
to better understand which factors may predict for local recurrences versus distant 
failures, so that we can tailor the appropriate adjuvant therapy regimen to each 
“high risk” patient.  
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The current study highlights the importance of pathological markers of prognosis in 
ampullary cancer. Future studies are needed to better delineate what specific 
markers should be assessed regularly in resected ampullary cancer patients. 
Additionally, clarifying what exactly should constitute adjuvant therapy will be of vital 
importance in improving outcomes in ampullary cancer. 
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